A phase 3 trial of The Medicines Company’s cholesterol-lowering drug inclisiran has met its primary endpoint. The company is yet to share the efficacy data that will show whether inclisiran can compete with other PCSK9 drugs.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,